Stanmore

Researchers are studying the use of epidural spinal cord stimulation (eSCS) to improve pelvic rehabilitation in adults with chronic supra-sacral spinal cord injury (SCI). This study focuses on managing bladder and bowel function issues, including neurogenic detrusor overactivity (NDO), by assessing the effects of eSCS combined with pelvic floor muscle training (PFMT). Participants will be monitored for changes in bladder capacity and other pelvic functions over time. The study has two phases. In Phase I, eligible participants will undergo screening and baseline assessments before receiving an implantable eSCS device with either percutaneous or paddle electrodes. The device will be implanted under the skin near the abdomen or buttocks. Participants will attend mapping sessions to optimize stimulation settings targeting bladder, bowel, and pelvic floor muscles. They will also learn a pelvic floor muscle training program for home use. In Phase II, participants will use the eSCS device and perform daily PFMT at home for 12 weeks, with periodic clinic visits and weekly phone calls for support and monitoring. During the study, participants will complete bladder and bowel diaries and undergo repeated assessments including urodynamics, anorectal physiology, and quality of life measures. Follow-up evaluations will occur at 3 and 6 months after the intervention. Participants may choose to keep or have the eSCS device removed after the trial, and researchers will continue to monitor outcomes. The primary outcome is the change in maximum cystometric bladder capacity from baseline through post-intervention and follow-up visits.

Researchers are conducting an international, multicenter, prospective, non-interventional observational registry to study patients with X-Linked Hypophosphatemia (XLH). The goal is to gather data to better understand the treatment approaches, disease progression, and long-term outcomes for both adults and children with XLH. This registry also supports a Post-Authorisation Safety Study (PASS) requested by the European Medicines Agency to monitor safety concerns related to burosumab treatment. Patients of all ages and genders with XLH can join the registry, regardless of whether they are currently receiving treatment. The registry collects data through a web-based system, including baseline, retrospective, and ongoing information from regular visits. Physicians will update patient data approximately every 12 months or more frequently if part of standard care, without any additional interventions required beyond routine clinical practice. Participants or their legal representatives provide informed consent, with assent sought from children when appropriate. Data collection involves recording clinical, radiological, biochemical, and genetic information supporting the diagnosis. Safety monitoring includes tracking treatment-related adverse events over a 10-year period. The registry follows patients over time, capturing comprehensive information to improve understanding of XLH and its management.

Researchers are conducting a global, multi-center, prospective post-market study to observe the long-term effectiveness of Boston Scientific neurostimulation systems in managing pain. The study aims to gather real-world clinical outcomes, economic value, and technical performance data of these commercially approved neurostimulation devices when used in routine clinical practice. The treatment involves an initial trial period using a Boston Scientific neurostimulation device for pain relief. Participants who experience a positive response during the trial may proceed to receive a permanent implant of the neurostimulation system. The therapy is tailored individually based on the investigator's judgment and standard care practices at each study site, following specific inclusion and exclusion criteria. Participants will be monitored throughout the trial and permanent implant phases to assess pain relief and overall treatment effectiveness. Assessments may include patient evaluations of pain and ability to complete study requirements. The study focuses on capturing comprehensive data to evaluate both clinical outcomes and device performance during regular use. Total participation duration depends on individual treatment progression from trial to permanent implant.

Injuries to the knee can damage the cartilage, which causes pain and limits movement, affecting daily activities like walking, sports, and work. Because cartilage does not repair itself well, surgery is often needed. This research evaluates how knee function changes after a cartilage repair surgery called autologous chondrocyte implantation (ACI), aiming to help doctors and patients understand surgery outcomes and identify issues that might be improved with physiotherapy. Untreated cartilage injuries may lead to arthritis, a painful lifelong condition, so effective treatment is important. The study involves adult patients waiting to have ACI surgery at one of seven hospitals in England. ACI is a two-step procedure where a patient's own cartilage cells are collected, grown in a lab, and then implanted into the injured area to regenerate cartilage. Participants will have two appointments at their hospital: one before surgery and one six months after surgery, where their knee movement, balance, and walking ability will be assessed. During the study, researchers will measure knee range of motion using a goniometer six months after surgery. Assessments will also include tests of balance and walking to evaluate functional recovery. The study is funded by Orthopaedic Research UK and the British Association for Surgery of the Knee and aims to improve understanding of functional outcomes after ACI surgery across multiple centers.

Researchers are conducting a Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effectiveness, safety, and tolerability of the drug INCB000928 in participants diagnosed with fibrodysplasia ossificans progressiva (FOP). This rare condition involves abnormal bone growth, and the study aims to understand how this medication may affect the disease. Participants will be randomly assigned to receive either INCB000928 or a placebo. Both treatments will be given once daily by mouth. The study includes different age groups, starting from 2 years old up to 99 years. The trial will monitor the occurrence of new abnormal bone growth lesions over a 24-week period. During the study, participants will undergo assessments including low-dose whole-body CT scans (excluding the head) to track new bone lesions. Researchers will evaluate the drug's safety and how the body processes it. Participants will be followed closely to monitor any side effects or changes in their condition over the study period.